Anastrozole and Exemestane Interaction

Avoid
Mechanism-based 75% confidence

Anastrozole and Exemestane have a potentially harmful interaction with 75% confidence. Both Anastrozole and Exemestane carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and liver and heart and pituitary, so monitoring these systems is recommended.

Compound Profiles

Anastrozole

Aromatase Inhibitor | Estrogen Management

Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Half-life: ~40-50 hours Typical dose: 0.25-0.5mg EOD or E3D (estrogen management) pct, anabolic
aromatase androgenicaromatase inhibitorestrogenichepatotoxic
View full profile

Exemestane

Steroidal Aromatase Inhibitor | Irreversible Estrogen Control

Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase as a substrate analogue and enters the enzyme's active site.

Half-life: ~24 hours Typical dose: 12.5mg EOD or 25mg E3D (estrogen management) pct, anabolic
androgen receptoraromatase androgenicaromatase inhibitorestrogenichepatotoxic
View full profile

Combined Organ Load

Gonads
elevated
Liver
elevated
Heart
moderate
Pituitary
low

Shared Safety Flags

2x 2 androgenic compounds (Anastrozole, Exemestane). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds share the aromatase-inhibitor safety flag (Anastrozole, Exemestane). Monitor accordingly.
2x 2 estrogenic compounds (Anastrozole, Exemestane). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.
2x 2 hepatotoxic compounds (Anastrozole, Exemestane). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (Anastrozole, Exemestane). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (Anastrozole, Exemestane). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the pct-agent safety flag (Anastrozole, Exemestane). Monitor accordingly.
2x 2 compounds share the teratogenic safety flag (Anastrozole, Exemestane). Monitor accordingly.

Frequently Asked Questions

Can I take Anastrozole with Exemestane?

Combining Anastrozole with Exemestane is not recommended. Both Anastrozole and Exemestane carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Anastrozole and Exemestane safe together?

This combination carries significant risk. Both Anastrozole and Exemestane carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Anastrozole and Exemestane?

Both Anastrozole and Exemestane carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anastrozole and Exemestane?

Anastrozole has a half-life of ~40-50 hours and Exemestane has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Anastrozole vs Exemestane

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.